triple hormone receptor agonist retatrutide for obesity ⭐️topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating #retatrutide, an investigational GIP / GLP-1 / glucagon agonist, in adults with or “overweight” PDF) Triple hormone receptor agonist

This is a major policy shift Medicare has historically excluded weight-loss drugs under the Part D anti-obesity exclusion

a visit copay or 20% coinsurance of the total)

These factors should be considered when interpreting the findings

But one question I get all the time is: If GLP-1s are so effective, why do doctors still prescribe phentermine? Thats a great question and the answer might surprise you

In addition, whether early initiation of GLP-1RA in patients with newly diagnosed T1D can preserve cell function remains to be determined in large RCTs

If you are in the Sheridan area, pop into Littleton Gynecology and Wellness and talk to one of our providers about whether this nutraceutical could help